the aid library

LIST OPTIONS

Filter

5994

Kenya national guidelines for cardiovascular diseases management. Handbook

Ministry of Health, Kenya (2018) CC

These guidelines for the prevention and management of cardiovascular diseases are a critical ingredient for streamlining care across the entire health services provision continuum. They are a strategic component in achieving universal health coverage, securing affordable heal... more

Download (354)

View PDF (536)

Strategy to respond to antimalarial drug resistance in Africa

World Health Organization WHO (2022) C_WHO

The Strategy to respond to antimalarial drug resistance in Africa is a technical and advocacy document, grounded in the best available evidence to date and aimed at minimizing the threat and impact of antimalarial drug resistance of Plasmodium falciparum parasites in Africa. Its objectives are to: i... more

Download (559)

View PDF (654)

RELATÓRIO MUNDIAL SOBRE A DEFICIÊNCIA

World Health Organization (WHO) and The World Bank (WB) (2011) C_WHO

Download (526)

View PDF (539)

Module: Psychoses

World Health Organization WHO (2015) C_WHO

Overview Learning objectives • Promote respect and dignity for people with psychoses. • Name common presentations of psychoses. • Name assessment principles of psychoses. • Name management principles of psychoses. • Perform an assessment for psychoses. • Use effective communicatio... more

Download (1736)

View PDF (3092)

Manual of the national tuberculosis and leprosy programme in Tanzania

Ministry of Health and Social Welfare, The United Republic of Tanzania (2006) C1

Download (315)

View PDF (546)

RELATÓRIO MUNDIAL SOBRE A DEFICIÊNCIA - Sumário

World Health Organization (WHO) & The World Bank (WB) (2011) C_WHO

Download (2986)

View PDF (1464)

National guideline for comprehensive package of HIV interventions for key populations

Ministry of Heatlh and Social Welfare, Tanzania (2014) C1

Download (563)

View PDF (548)

Robson Classification: Implementation Manual

World Health Organization (2017) C_WHO

In 2015, WHO proposed the use of the Robson classification (also known as the 10-group classification) as a global standard for assessing, monitoring and comparing caesarean section rates both within healthcare facilities and between them. The system classifies all women into one of 10 categories t... more

Download (358)

View PDF (550)

World Report on Vision

World Health Organization WHO (2019) C_WHO

At present at least 2.2 billion people around the world have a vision impairment, of whom at least 1 billion have a vision impairment that could have been prevented or is yet to be addressed. The world faces considerable challenges in terms of eye care, including inequalities in the coverage and qua... more

Download (264)

View PDF (288)

Interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (‎CNBG)‎, Sinopharm (28 October 2021), updated 15 March 2022

World Health Organization WHO (2022) C_WHO

These WHO interim recommendations for use of the COVID-19 vaccine BIBP produced by Sinopharm were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below. Th... more

Download (279)

View PDF (607)

Response to the Ukraine Crisis: interim report, February to June 2022

World Health Organization WHO, Regional Office of Europe (2022) C_WHO

Saving lives is the priority of WHO’s response in Ukraine. WHO works to ensure time-critical, lifesaving multisectoral assistance, non-discriminatory access to emergency and essential health services and priority prevention programmes, and laying the foundation for longer-term health systems recov... more

Download (314)

View PDF (306)

Manual de Seguimiento Fármaco Terapéutico en Usuarios Ambulatorios

Ahumada A., Ebensperger R. et al Ministerio de Salud Chile (2019) C2

Este manual pretende estandarizar la práctica del SFT para que el QF pueda trabajar con los usuarios de forma consistente y estandarizada a nivel nacional.

Download (462)

View PDF (463)

Supporting the routine use of evidence during the policy-making process: a WHO checklist

World Health Organisation (WHO) (2023) C_WHO

This checklist is for any organization or person supporting the routine use of evidence in the process of policy-making. Evidence-informed policy-making (EIPM) is essential for achieving the Sustainable Development Goals (SDGs) and universal health coverage (UHC). Its importance is emphasized in WH... more

Download (256)

View PDF (405)

HIV/AIDS surveillance in Europe 2017

A. Pharris; A. Stengaard World Health Organization (Europe); European Centre for Disease Prevention and Control (2017) C_WHO

2016 data The report was coordinated by Anastasia Pharris and Annemarie Stengaard. Report review and production support were provided by Andrew J. Amato-Gauci, Mike Catchpole, Denis Coulombier, Masoud Dara, Nedret Emiroglu, Rachel Katterl, Shahin Khasiyev, Valentina Lazdina, Teymur Noori, Marc... more

Download (1945)

View PDF (2270)

Kenya HIV Prevention Revolution Road Map. Countdown to 2030

Ministry of Health, Kenya (2014) C1

Download (383)

View PDF (375)

Multi-Professional Patient Safety Curriculum Guide

World Health Organization WHO (2011) C_WHO

The Multi-professional Patient Safety Curriculum Guide (2011) was developed to assist in the teaching of patient safety in universities and schools in the fields of dentistry, medicine, midwifery, nursing and pharmacy. It also supports the on-going training of all health care professionals. The C... more

Download (312)

View PDF (436)

Innovation in deinstitutionalization: a WHO expert survey

World Health Organization WHO (2014) C_WHO

Based on the survey, five principles for deinstitutionalization were identified: community-based services must be in place; the health workforce must be committed to change; political support at the highest and broadest levels is crucial; timing is key; and additional financial resources are needed.

Download (487)

View PDF (707)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (346)

View PDF (315)

Quick guide to video-supported treatment of tuberculosis (2020)

World Health Organization WHO, Regional Office of Europe (2020) C_WHO

Despite being a curable and preventable disease, tuberculosis (TB) remains as one of the major challenges for health systems, globally. Every year, TB affects more than 10 million people and kills more than 1.4 million people. WHO’s Digital Health for the End TB Strategy – an Agenda for Action o... more